Webpackaging logo

Self medication autoinjector now a smart device with easy-to-use SmartPilot

Europe, France, Switzerland, France, Switzerland, Germany, Austria, Germany, Austria, Health, Pharmaceuticals, Secondary Packaging, Labels, Active, Smart Packaging, RFID Tracking, Sustainable Packaging, Reusable Packaging, Labelling, Sleeving, Contract Manufacturing, Processing, Blending, Recycling, Packaging Awards

NFC-Label by Schreiner MediPharm for Ypsomed’s SmartPilot™ Supports Smart Self-Medication

Schreiner MediPharm, a Germany-based global provider of specialty  pharmaceutical labeling solutions for over 65 years, in cooperation with Swiss-based Ypsomed, has developed an NFC-Label that is applied to the YpsoMate® autoinjector.

Stored information about the medication is transmitted to its electronic add-on – the novel SmartPilot™ - and is recorded via the autoinjector and logged by the SmartPilot™. The resulting connected device enhances the safety of patients and assists them in the self-administration of medicines to better comply with prescribed therapies.

YpsoMate® is an autoinjector for self-medication of a wide range of pharmaceutical substances and in a diverse range of therapeutic areas. To turn this injection platform into a smart device, Ypsomed developed the easy-to-use SmartPilot™ – a reusable add-on with embedded sensor technology.

The autoinjector is pushed into the SmartPilot™ and is automatically recognized due to the NFC-Label applied to the
injection aid. The information about the medication stored on the NFC chip is transmitted via the SmartPilot™ to a related smartphone app via Bluetooth connection.

The technology behind this connected device is the interlinking of diverse sensors and the label with an integrated NFC chip, which Schreiner MediPharm adapted for YpsoMate®. The NFC chip identifies and authenticates the medicine and checks its expiration date.

According to the prescribed therapy, the patient can be guided in real time through the injection process by means of the SmartPilot™ sensors, and feedback on the correct administration of the medicine can be transmitted. It is also possible to store the entire injection history in detail – from injection time and success through to patient well-being
— and to share it with other stakeholders. The attending physician, for instance, is then able to use this information to adjust the continuing therapy plan.

“The integration of NFC technology, which has to ensure reliable reading, in a very small space posed the primary challenge in this label development. Subsequent ease of processing was another specified objective,” explains Arne Rehm, Product Manager RFID/NFC Solutions at chreiner MediPharm.

“The cooperation between Ypsomed and Schreiner MediPharm yielded an innovative and complete solution for pharmaceutical manufacturers, who are now able to provide patients with the SmartPilot™, a valuable tool supporting them in self-medication efforts,” adds Andreas Schneider, Innovation & Business Development Manager at Ypsomed.

See also

Schreiner MediPharm and Applied DNA Sciences offer forensic counterfeit-proof feature for pharma labels

Schreiner MediPharm, a Germany-based global provider of specialty pharmaceutical labeling solutions, now offers a new forensic authentication feature for pharmaceutical labels in cooperation with Applied DNA Sciences. SigNature DNA is a high-security feature based on DNA markers with which pharmaceutical manufacturers can protect products against counterfeiting, and patients against potential health risks.

Schreiner MediPharm develops smart blister pack for clinical trial

Schreiner MediPharm has developed a smart blister pack for digital patient compliance monitoring to enhance medication adherence by clinical trial participants. Schreiner MediPharm implemented the smart packaging solution together with the Dutch technology company ECCT (Experts in Communications and Connectivity Technology). Employment of this electronic tool to manage and track processes during clinical trials marks a milestone for the pharmaceutical manufacturer.

Schreiner MediPharm supports Biotest AG with “Late Stage Customization” service for supply chain agility

Flexible production of functional labels successfully addresses market segmentation. Schreiner MediPharm, a Germany-based global provider of specialty pharmaceutical labeling solutions for over 65 years, recently implemented a special Late Stage Customization service in partnership with its customer, Biotest AG. The new process allows for faster production of functional labels on short demand. As a result, Biotest benefits from greater flexibility and is able to respond to market requirements with requisite agility, while Schreiner MediPharm assists its customer in meeting the demands of current segmentation trends in the pharmaceutical industry.

  • Company News
  • English
  • Modified 14 May 2019
  • Hits 777